Search the Newsreel

Earnings Flash (MTD) Mettler-Toledo International Inc. Reports Q2 Revenue $1.03B, vs. FactSet Est of $1.03B

Mettler-Toledo International Inc. (MTD) reported its Q2 revenue at $1.03 billion, matching FactSet's estimate. The company's Q2 adjusted earnings and revenue both saw an increase, and Mettler-Toledo also provided Q3 adjusted EPS guidance in the range of $12.00 to $12.15. This financial update aligns …

Mettler Toledo reports Q2 revenue $1.027B, adjusted EPS $11.46, strong margin improvement

Mettler Toledo (MTD) announced strong Q2 2026 results with net sales of $1.027 billion and adjusted diluted EPS of $11.46, marking a 14% increase year-over-year. The company attributed its margin and earnings gains to organic sales growth, improved market conditions, and benefits from its …

Mettler-Toledo: Q2 Earnings Snapshot

Mettler-Toledo International Inc. reported strong second-quarter results, with net income of $232.9 million, or $11.55 per share. Adjusted earnings of $11.46 per share surpassed Wall Street expectations, as did their revenue of $1.03 billion. The company also provided an optimistic outlook for its third …

Mettler-Toledo International Inc. Reports Second Quarter 2026 Results

Mettler-Toledo International Inc. (NYSE: MTD) announced strong second-quarter 2026 results, with reported sales increasing 4% and diluted EPS at $11.55. Adjusted EPS rose 14% to $11.46, driven by robust organic sales growth, particularly in China and emerging markets. The company also provided an optimistic …

Mettler-Toledo earnings on deck as growth expectations cool

Mettler-Toledo International Inc. is preparing to report its second-quarter results, with analysts expecting earnings of $10.79 per share on revenue of $1.03 billion, reflecting moderating growth expectations. Investors will be observing organic revenue trends, margin performance, and management's outlook for the second half of …

Toll Brothers Opens Cambric Village - Enclave Collection in Greenville, South Carolina

Toll Brothers has opened Cambric Village, a new luxury home community in Greenville, South Carolina, featuring the Enclave Collection of single-family homes. These homes offer 4 to 5 bedrooms, flexible spaces, and are priced from the low $800,000s, with townhomes to follow in summer …

Bristol-Myers, Merck win FDA review for Reblozyl label expansion

The FDA has accepted Bristol-Myers Squibb's marketing application for an expanded U.S. label for its anemia therapy, Reblozyl. This drug was developed in partnership with Merck. The announcement was made during Bristol-Myers Squibb's Q2 2026 financial report.

Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views

U.S. stocks saw broad gains, with the Dow up 0.40%, NASDAQ surging 2.08%, and the S&P 500 rising 0.89%. Bristol-Myers Squibb reported better-than-expected Q2 earnings and raised its FY2026 guidance, while gold prices surged 3%. Several companies, including Columbus McKinnon, Marketaxess Holdings, and Xerox …

Toll Brothers Announces Tribute at Valor is Now Open in Kuna, Idaho

Toll Brothers has announced the opening of Tribute at Valor, a new luxury master-planned community in Kuna, Idaho, near Boise. This community features diverse single-family home designs ranging from 1,400 to over 4,700 square feet, with pricing starting in the mid-$400,000s. Residents will have …

Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat

Bristol Myers Squibb has once again delayed the phase 3 data readout for its Alzheimer's disease psychosis drug, Cobenfy, moving the expected arrival of data to early 2027 due to slower patient enrollment and relapse event accrual. Despite this setback and a muted launch …

Capitol Federal Financial stock hits 52-week high at $8.86

Capitol Federal Financial Inc. (CFFN) stock has reached a new 52-week high of $8.86, with the stock currently trading at $8.99 and boasting a market capitalization of $1.09 billion. The company has experienced significant growth over the past year, with a 1-year total return …

Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 5.7% year on year to $12.97 billion. The company's full-year revenue guidance of …

Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Bristol Myers Squibb (BMY) reported $12.97 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 5.7%. EPS of $2.04 for the same period compares to $1.46 a year ago. The reported revenue compares to the Zacks Consensus Estimate of …

Bristol Myers Squibb erhöht die Prognose für 2026 nach besser als erwarteten Ergebnissen im zweiten Quartal.

Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat

Bristol Myers Squibb has increased its full-year revenue and earnings forecast for 2026 following better-than-expected second-quarter results. Strong sales of its blood thinner Eliquis, along with newer drugs like Camzyos and Reblozyl, drove revenue to $12.97 billion, surpassing analyst estimates. The company now expects …

Toll Brothers, Inc. Revenue Breakdown – HAM:TLK

Toll Brothers, Inc. (HAM:TLK) reported its revenue breakdown. In the last year, the company generated 9.51 billion EUR in total revenue, with its Home Building segment contributing the most at 9.40 billion EUR, a slight decrease from the previous year's 9.71 billion EUR. The …

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

Bristol Myers Squibb reported its second-quarter 2026 financial results, which can be viewed on the company's Investor Relations website. The biopharmaceutical company hosted a conference call and live audio webcast for analysts and investors to discuss these results. A replay of the webcast will …

Bristol-Myers stock gains after Q2 2026 beat (BMY:NYSE)

Bristol-Myers Squibb (BMY) raised its full-year outlook after reporting better-than-expected Q2 2026 financials, driven by strong sales of its cancer therapies. The company reported approximately $13.0B in revenue, a ~6% YoY growth. The updated guidance for full-year revenue is $49.0B–$50.0B and adjusted EPS is …

Bristol-Myers Squibb raises annual outlook as Q2 tops estimates; shares up

Investing.com -- Bristol-Myers Squibb shares rose more than 1% in premarket trading Thursday after the drugmaker posted second-quarter results well ahead of expectations and raised its full-year guidance. The company reported earnings per share of $2.04, beating the analyst estimate of $1.61. Revenue came …

Bristol Myers Raises Guidance After Record-Breaking Sales

Bristol Myers Squibb Co. increased its sales and profit outlook for 2026 following better-than-expected second-quarter demand for its drugs, particularly newer treatments for heart conditions and cancer. The company now expects full-year sales between $49 billion and $50 billion, up from an earlier forecast, …

Bristol-Myers Squibb superaron 0.43$ las previsiones de BPA en el segundo trimestre del año

BRISTOL-MYERS SQUIBB ($BMY) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. Revenue: Total revenue increased 5% year-over-year to approximately $13 billion. Growth Portfolio Revenue: Rose 14% to $7.6 billion, now representing nearly 60% of total revenue. Eliquis Revenue: Approximately $4.5 billion, up 21%, driven by strong demand and market …

Bristol Myers Lifts Outlook as Profit, Revenue Rise

Bristol Myers Squibb raised its full-year earnings and revenue outlook after reporting increased profit and revenue in the latest quarter. The biopharmaceutical company now forecasts earnings of $6.75 to $7 per share and revenue of $49 billion to $50 billion, an increase from its …

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

Bristol Myers Squibb significantly raised its full-year revenue and profit forecasts for 2026 after reporting strong second-quarter results, driven by robust sales of blood thinner Eliquis and newer drugs like Camzyos and Reblozyl. The company's strategy to counter sales declines from older medicines facing …

How To Earn $500 A Month From Bristol-Myers Squibb Stock Ahead Of Q2 Earnings

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Bristol-Myers Squibb Company will release earnings for its second quarter before the opening bell on Thursday, July 30. Analysts expect the company to report quarterly earnings of …

Toll Brothers Inc (TOL) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Toll Brothers Inc (TOL), including its price momentum, support and resistance levels, and various technical indicators and moving averages. While the stock currently shows a neutral signal based on technical analysis, it highlights specific buy and sell …

Mettler-Toledo International, Inc. $MTD Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. decreased its holdings in Mettler-Toledo International, Inc. (NYSE:MTD) by 11.7% in the first quarter, selling 1,039 shares and retaining 7,834 shares worth $9.88 million. Other institutional investors have also adjusted their stakes, with overall institutional ownership at 95.07%. Mettler-Toledo recently reported …

Edgestream Partners L.P. Buys Shares of 154,427 Bristol Myers Squibb Company $BMY

Edgestream Partners L.P. has acquired a new position in Bristol Myers Squibb Company (NYSE:BMY), purchasing 154,427 shares valued at approximately $9.366 million during the first quarter. This increased institutional ownership in the biopharmaceutical company, with other major investors like Vanguard Group Inc., State Street …

First Trust Advisors LP Sells 23,908 Shares of Mettler-Toledo International, Inc. $MTD

First Trust Advisors LP significantly reduced its stake in Mettler-Toledo International, Inc. (MTD) by selling 23,908 shares, retaining 14,060 shares valued at approximately $17.7 million. Despite mixed analyst ratings and an average price target of $1,408.55, Mettler-Toledo exceeded quarterly earnings expectations with $8.91 EPS …

Arrowstreet Capital Limited Partnership Increases Position in Capitol Federal Financial $CFFN

Arrowstreet Capital Limited Partnership increased its holdings in Capitol Federal Financial (CFFN) by 10.5% in the first quarter, bringing its total to 3.26 million shares valued at $23.3 million. Institutional investors collectively own 88.51% of the company's stock. Capitol Federal Financial recently reported strong …

Bristol-Myers Squibb (NYSE: BMY) grows Q2 revenue to $12.97B

Informe de resultados: Bristol Myers supera las estimaciones del segundo trimestre de 2026

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates

Bristol Myers Squibb Lifts Full-Year Guidance After Strong Second-Quarter Earnings Beat

Bristol Myers Squibb hebt Prognose an nach Wachstumsschub - Aktie steigt vorbörslich

Toll Brothers (TOL) Opens New Luxury Communities With Valuation Still In Focus

Toll Brothers (TOL) has recently opened new luxury communities across several states and a new Design Studio in Texas, bringing attention to its stock. Despite recent volatility, with an 8.9% drop over 30 days, the stock is up 26.7% over the last year and …